Stimuliver
Klaus Langhoff-Roos serves as Chief Executive Officer at BioLamina since August 2024, with additional roles as a Board Member at UV Medico and Stimuliver, focusing on advanced healthcare solutions. Previously, Klaus held the position of Chief Executive Officer at StemMedical® from July 2022 to April 2024, contributing to the development of innovative cell-based therapies. An extensive career at Novo Nordisk lasted from 2004 to 2022, where Klaus progressed through various leadership roles, including Corporate Vice President for Cell Therapy and GLP-1 portfolio, achieving significant growth and successful product launches. Additionally, Klaus's experience includes management consulting at PA Consulting Group and a solid educational background with an MSc in Political Science and Economics from the University of Copenhagen.
This person is not in the org chart
This person is not in any teams
Stimuliver
Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list. Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.